This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Peregrine Pharma: The Partner Guessing Game

TUSTIN, Calif. ( TheStreet) --Further thoughts on Peregrine Pharmaceuticals (PPHM - Get Report) following its conference call Monday discussing the bavituximab lung cancer data:

Peregrine says the bavituximab survival benefit observed in the phase II study is "similar" in patients across geographies. No details were offered, however, nor did the company say when we might see those data.

"We couldn't have conducted a more well-balanced clinical trial," company executives said.

Fine, but let's see the data. Real data, please! Let's see how lung cancer patients enrolled in India and Eastern Europe fared against those coming from the U.S.

It may have been my bavituximab skepticism shining through, but it certainly sounded to me as if Peregrine executives were lowering expectations for the survival results from the other phase II study in first-line lung cancer. We're supposed to see those survival data before the end of the year, which could go a long way to supporting or debunking Friday's bavituximab data in the second line.

Partnering discussions for bavituximab are moving forward at a "very active pace," said Peregrine. The company wants a deal in place before it meets with FDA later this year to clear the phase III study design. At the very least, Peregrine says to expect a partnership before the phase III study begins in the middle of next year.

Let's play a parlor game: Guess the bavituximab partner. AstraZeneca (AZN - Get Report) is perhaps the most likely suitor out of Europe given its desperation for new pipeline drugs.

Novartis (NVS) is a maybe, except for the bad taste left in its mouth from the Antisoma partnership that ended in failure in 2010. Antisoma's lung cancer drug was similar to Peregrine's in that they both target lung cancer blood vessels. Does Novartis want to go down this route again?

Hard to see GlaxoSmithKline (GSK - Get Report) or Roche (RHHBY) interested in bavituximab given their focus on anti-PD-1 antibodies . PD-1 is a hot cancer immunotherapy target, especially after promising data were presented at this year's ASCO conference in June.

Merck KGaA loves lung cancer immunotherapy but is already engaged to Oncothyreon (ONTY).

Closer to home, Bristol-Myers Squibb (BMY - Get Report) and Merck (MRK) are also working on anti-PD1 antibodies. Bristol, in fact, is moving a PD-1 drug into phase III studies, including in lung cancer. Again, why pay money to license bavituximab if you're already working on a competing cancer immunotherapy technology -- and one that has a lot more buzz.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AZN $69.45 0.00%
BMY $68.30 0.00%
GSK $45.26 0.00%
LLY $74.30 0.00%
PFE $34.28 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs